Page 152 - TD-3-4

Tumor Discovery Primarily enucleated RB patient’s analysis

middle-income countries. In such contexts, awareness References
programs, training of specialized ophthalmologists 1. Roy SR, Kaliki S. Retinoblastoma: A major review.
through fellowships, professional collaboration, and Mymensingh Med J. 2021;30(3):881-895.
effective referrals can promote early detection and reduce
the advanced presentation of RB. 2. Zhang Y, Wang Y, Zhi T, Jin M, Huang D, Ma X. Clinical
characteristics, treatment and prognosis of infants with
This retrospective study may have biases in some data, retinoblastoma: A multicenter, 10-year retrospective
and it only reports the overall survival rate. analysis. BMC Pediatr. 2023;23(1):229.

5. Conclusion doi: 10.1186/s12887-023-03984-5
3. Stacey AW, Bowman R, Foster A, et al. Incidence of
Enucleation marks the beginning, not the end, of treatment retinoblastoma has increased: Results from 40 European
in advanced RB cases. Detailed histopathology reports countries. Ophthalmology. 2021;128(9):1369-1371.
specifying HRFs are crucial for further management. doi: 10.1016/j.ophtha.2021.01.024
Delayed presentation complicates treatment and is a
poor prognostic factor due to higher metastasis risks. 4. Fernandes AG, Pollock BD, Rabito FA. Retinoblastoma in
To improve outcomes, we should prioritize awareness, the United States: A 40-year incidence and survival analysis.
early presentation, accurate histopathological reporting, J Pediatr Ophthalmol Strabismus. 2018;55(3):182-188.
and human resource development alongside appropriate doi: 10.3928/01913913-20171116-03
treatment. 5. Global Retinoblastoma Study Group, Fabian ID, Abdallah E,
et al. Global retinoblastoma presentation and analysis by
Acknowledgments national income level. JAMA Oncol. 2020;6(5):685-695.

None. doi: 10.1001/jamaoncol.2019.6716. Erratum in: JAMA
Oncol. 2020;6(11):1815.
Funding
doi: 10.1001/jamaoncol.2020.5133
None.
6. Chevez-Barrios P, Eagle RC, Marback EF. Histopathologic
Conflict of interest features & prognostic factors. In: Clinical Ophthalmic
Oncology. Berlin: Springer; 2019. p. 221-237.
The authors declare they have no competing interests. doi: 10.12669/pjms.38.ICON-2022.5787
Author contributions 7. Global Retinoblastoma Study Group. The Global
Retinoblastoma Outcome Study: A prospective, cluster-
Conceptualization: Soma Rani Roy based analysis of 4064 patients from 149 countries. Lancet
Formal analysis: Sujit Kumar Biswas Glob Health. 2022;10(8):e1128-e1140.
Investigation: Rahat Anjum doi: 10.1016/S2214-109X(22)00250-9
Methodology: Soma Rani Roy
Writing – original draft: Soma Rani Roy 8. Yaqoob N, Mansoor S, Aftab K, Kaleem B, Hamid A, Jamal S.
Writing – review & editing: Sujit Kumar Biswas High risk histopathological factors in retinoblastoma in
upfront enucleated eyes: An experience from a tertiary care
Ethics approval and consent to participate centre of Pakistan. Pak J Med Sci. 2022;38(2):369-374.
doi: 10.12669/pjms.38.ICON-2022.5787
This study was approved by the local IRB of the Chittagong
Eye Infirmary and Institute of Community Ophthalmology. 9. Shields CL, Mashayekhi A, Demirci H, Meadows AT,
Informed consent written and verbally were obtained from Shields JA. Practical approach to management of
the parents or legal guardians of the patients before their retinoblastoma. Arch Ophthalmol. 2004;122(5):729-735.
participation. doi: 10.1001/archopht.122.5.729
Consent for publication 10. Chantada G, Doz F, Antoneli CB, et al. A proposal for an
international retinoblastoma staging system. Pediatr Blood
Consent was taken from the parents or legal guardians of Cancer. 2006;47(6):801-805.
the patients to use their data and images in this study. doi: 10.1002/pbc.20606

Availability of data 11. Thaung C, Karaa EK. Standard reporting of high-risk
histopathology features in retinoblastoma. Community Eye
Not applicable. Health. 2018;31(101):31-33.

Volume 3 Issue 4 (2024) 9 doi: 10.36922/td.4336